Data Sheet 1_Neurological and hematological safety profiles of GSK-3β inhibitors: insights from multi-database pharmacovigilance and experimental validation.zip

Background<p>Glycogen synthase kinase 3 beta (GSK-3β) inhibitors have received substantial attention for their therapeutic potential; however, their systemic safety profile remains incompletely characterized.</p>Objective<p>This study characterized the research landscape and exploratory safety-reporting signals associated with agents with reported GSK-3β activity by integrating bibliometric analysis, pharmacovigilance, and preliminary experimental assessment.</p>Methods<p>A multi-layered framework included bibliometric analysis, disproportionality analyses of FAERS, JADER, and CVARD reports, and transcriptomic profiling.

SH-SY5Y cells were treated with 9-ING-41 (1 μM, 24 h); cell viability, qRT-PCR, and DCFH-DA-based intracellular oxidative-stress measurements were assessed.</p>Results<p>Bibliometric analysis showed sustained growth in GSK-3β-related research. Pharmacovigilance identified neurological and hematologic disproportionality signals across 27 System Organ Classes. In SH-SY5Y cells, 9-ING-41 was associated with modest changes in neuronal-function, inflammatory-response, and GSK-3β/Wnt-pathway transcripts, increased DCFH-DA fluorescence, and high cell viability.